New Website Launch

NEWCASTLE UPON TYNE, UK, 29 APRIL 2022. QuantuMDx Group Limited (“QuantuMDx”), is thrilled to announce the launch of a new website www.quantumdx.com/.

Our new website features improved functionalities and easy access to essential information about our solution and our brand in a fully responsive and more attractively designed format.

“This platform is part of the ongoing evolution of our brand. We kicked off this project with the intention to reflect the personality of QuantuMDx – a progressive medical technology company passionate about empowering the world to control disease and reduce suffering. We wanted to not only refresh the look and feel of our website, but also to tell a story around our solution and enhance the user experience.” commented Fiona Smith, VP Marketing at QuantuMDx.

With this website, we have also improved our way to provide updates on the topic that we are passionate about – rapid multiplex diagnostic solutions for the real world – through a section called Insights. Via content being posted continuously under News, Blogs and Events, visitors can now see in a blink what’s happening in our company.

We’d love to hear what you think about our new website, if you have any suggestions or feedback, leave us a comment on our LinkedIn page.

About QuantuMDx:

QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need, for anyone, anywhere.

QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics. 

Q-POC™ is a rapid, simple to use, portable, sample to answer PCR device and has been designed for use in a wide range of settings, such as hospitals, clinics, pharmacies, and workplace testing providing accurate PCR results at the Point of Need. Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. It tests multiple targets of the disease for a future proof COVID-19 testing solution at the Point of Need. 

QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years. 

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.local


For media enquiries and interview requests:

Emma Long, Marketing Communications Manager, QuantuMDx,
M: +44 (0) 7495 341 930  T: +44 (0) 870 803 1234  / emma.long@quantumdx.com

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications,
+44 (0)20 3709 5700 / quantumdx@consilium-comms.com

For investor enquiries:

David Wilson, Nigel Barnes and Jeff Glushakow, WG Partners (Financial Adviser to QuantuMDx), +44 (0)20 3705 9330 / quantumdx@wgpartners.co.uk